1. Generics Bulletin
  2. >>Policy & Regulation

Rebate Reprieve For Generics And Biosimilars Added To Build Back Better Act

Generics Facing Shortages And Biosimilars Are Now Exempt From Rebate Scheme

 
• By Chloe Kent

The Build Back Better Act has been updated to exempt generics experiencing or at risk of shortage from its planned inflation rebates, as well as biosimilars. But the US Association for Accessible Medicines has called for further changes to the proposed bill to protect off-patent drugs.

Wooden letters on dark background
Select generics and biosimilars have been exempted from Build Back Better's rebate scheme • Source: Alamy

An update to the language of the Biden administration’s proposed Build Back Better Act has been welcomed by the US Association for Accessible Medicines, after biosimilars and certain generic drugs were exempted from its planned inflation rebates – but the organization has still called for further changes to be made to the draft legislation.

The latest version of the bill now states that generic drugs under Medicare Part D that are in shortage can...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Policy & Regulation

More from Generics Bulletin

Pipeline And Parent: Meitheal CEO Shea Talks Paclitaxel And What’s Next

 
• By Dean Rudge

In an exclusive interview, Meitheal Pharmaceuticals CEO Tom Shea discusses the company’s oncology strategy following the recent launch of generic Abraxane, alongside discussion of complex injectables, the biosimilars pipeline, and how $300m in backing is fueling the company's next phase of growth.

Endo Offloads Paladin As Shareholders Approve Mallinckrodt Merger

 
• By Dave Wallace

As it prepares to complete its $6.7bn merger with Mallinckrodt, Endo has divested its International Pharmaceuticals business – consisting primarily of Canadian specialty firm Paladin Pharma – to Knight Therapeutics.

Canada Joins Global Push To Drop Costly Clinical Trials For Biosimilars

 
• By Neena Brizmohun

Health Canada’s proposal to no longer require biosimilar manufacturers to prove the safety and efficacy of their product through Phase III clinical trials marks a pivotal change in Canada’s regulatory approach.